Computational selection of antibody-drug conjugate targets for breast cancer

Download
  1. (PDF, 1 MB)
  2. Get@NRC: Computational selection of antibody-drug conjugate targets for breast cancer (Opens in a new window)
DOIResolve DOI: http://doi.org/10.18632/oncotarget.6679
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for:
TypeArticle
Journal titleOncotarget
ISSN1949-2553
SubjectADC; drug target; microarray; feature selection; ensemble classification
AbstractThe selection of therapeutic targets is a critical aspect of antibody-drug conjugate research and development. In this study, we applied computational methods to select candidate targets overexpressed in three major breast cancer subtypes as compared with a range of vital organs and tissues. Microarray data corresponding to over 8,000 tissue samples were collected from the public domain. Breast cancer samples were classified into molecular subtypes using an iterative ensemble approach combining six classification algorithms and three feature selection techniques, including a novel kernel density-based method. This feature selection method was used in conjunction with differential expression and subcellular localization information to assemble a primary list of targets. A total of 50 cell membrane targets were identified, including one target for which an antibody-drug conjugate is in clinical use, and six targets for which antibody-drug conjugates are in clinical trials for the treatment of breast cancer and other solid tumors. In addition, 50 extracellular proteins were identified as potential targets for non-internalizing strategies and alternative modalities. Candidate targets linked with the epithelial-to-mesenchymal transition were identified by analyzing differential gene expression in epithelial and mesenchymal tumor-derived cell lines. Overall, these results show that mining human gene expression data has the power to select and prioritize breast cancer antibody-drug conjugate targets, and the potential to lead to new and more effective cancer therapeutics.
Publication date
LanguageEnglish
AffiliationInformation and Communication Technologies; Human Health Therapeutics; National Research Council Canada
Peer reviewedYes
NPARC number21277175
Export citationExport as RIS
Report a correctionReport a correction
Record identifier9bbe49d3-3fac-41c3-80a2-b228d4d02215
Record created2016-01-04
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)